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Background: Oxidative stress is involved in development of diabetes complications. Extracellular superoxide
dismutase (EC-SOD, SOD3) is a major extracellular antioxidant enzyme and is highly expressed in arterial walls.
Advanced oxidation protein products (AOPP) and 8-iso-prostaglandin (isoprostane) are markers of oxidative stress.
We investigated association of SOD3 gene variants, plasma concentrations of EC-SOD, AOPP and isoprostane with
myocardial infarction and mortality in diabetic patients.
Methods: We studied three cohorts designed to evaluate the vascular complications of diabetes: the GENEDIAB
study (469 participants with type 1 diabetes at baseline; follow-up data for 259 participants), the GENESIS study
(603 participants with type 1 diabetes at baseline; follow-up data for 525 participants) and the DIABHYCAR study
(3137 participants with type 2 diabetes at baseline and follow-up). Duration of follow-up was 9, 5, and 5 years,
respectively. Main outcome measures were incidence of myocardial infarction, and cardiovascular and total
mortality during follow-up. Six single nucleotide polymorphisms in the SOD3 locus were genotyped in the three
cohorts. Plasma concentrations of EC-SOD, AOPP, and isoprostane were measured in baseline samples of
GENEDIAB participants.
Results: In GENEDIAB/GENESIS pooled cohorts, the minor T-allele of rs2284659 variant was inversely associated
with the prevalence at baseline (Odds Ratio 0.48, 95% CI 0.29–0.78, p = 0.004) and the incidence during follow-up
of myocardial infarction (Hazard Ratio 0.58, 95% CI 0.40–0.83, p = 0.003) and with cardiovascular (HR 0.33, 95% CI
0.08–0.74, p = 0.004) and all-cause mortality (HR 0.44, 95% CI 0.21–0.73, p = 0.0006). The protective allele was
associated with higher plasma EC-SOD and lower plasma AOPP concentrations in GENEDIAB. It was also inversely
associated with incidence of myocardial infarction (HR 0.75, 95% CI 0.59–0.94, p = 0.01) and all-cause mortality
(HR 0.87, 95% CI 0.79–0.97, p = 0.008) in DIABHYCAR.
Conclusions: The T-allele of rs2284659 in the promoter of SOD3 was associated with a more favorable plasma
redox status and with better cardiovascular outcomes in diabetic patients. Our results suggest that EC-SOD plays
an important role in the mechanisms of vascular protection against diabetes-related oxidative stress.
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Diabetes mellitus is associated with increased mortality
rates [1,2]. Despite significant improvement of medical
care during late decades, life expectancy of patients with
type 1 or type 2 diabetes remains reduced as compared
to age- and sex-matched nondiabetic subjects [1,2]. Car-
diovascular disease is the leading cause of mortality and
morbidity in patients with diabetes [1,2], and diabetic
patients have a 3-fold higher risk than nondiabetic indi-
viduals of developing atherosclerosis and its clinical
complications [1,3]. It is now well established that sus-
ceptibility to cardiovascular complications in diabetic pa-
tients are modulated by genetic factors [4].
Oxidative stress plays a major role in the development
of microvascular and macrovascular complications of
diabetes [5]. Superoxide dismutase (SOD) is a class of
enzymes that catalyze the dismutation of superoxide into
oxygen and hydrogen peroxide [6], and modulate the redox
status of eukaryotic cells. The extracellular superoxide dis-
mutase (EC-SOD or SOD3) is a major extracellular anti-
oxidant enzyme, mainly located in the lymph, synovial
fluid and plasma [7]. EC-SOD is highly expressed in blood
vessels, particularly in arterial walls and represents up to
70% of the SOD activity in this tissue [7]. EC-SOD plays an
important role in the protection against cardiovascular oxi-
dative stress [8,9]. Advanced oxidation protein products
(AOPP) and 8-iso-prostaglandin (isoprostane) were identi-
fied as markers of oxidative stress in patients with heart
disease [10,11]. In the present study we investigated associ-
ations of allelic variation in the SOD3 gene with the risk of
myocardial infarction, cardiovascular death and all-cause
mortality in two prospective cohorts of type 1 diabetic pa-
tients and one prospective cohort of type 2 diabetic pa-
tients. Correlations of genotypes, clinical outcomes, and
circulating levels of EC-SOD, AOPP and isoprostane were
also studied in type 1 diabetic participants.
Methods
Participants: GENEDIAB and GENESIS cohorts of type 1
diabetic patients
We studied two multicenter binational (Belgium and
France) cohorts of type 1 diabetes patients designed to
study the vascular complications of diabetes. The GENE-
DIAB (GEnétique de la NEphropathie DIABétique) study
was conducted in 494 people with type 1 diabetes and
pre-proliferative or proliferative retinopathy [12]. GEN-
ESIS France-Belgium was a family-based study including
662 probands with type 1 diabetes and non-proliferative
or proliferative retinopathy, and 578 first-degree relatives
[13]. In the present investigation, we analyzed at baseline
469 GENEDIAB participants and 603 GENESIS pro-
bands for whom DNA samples were available. Clinical
characteristics of GENEDIAB and GENESIS participants
are shown in the Additional file 1: Table S1. In aprospective observational study, subsets of GENEDIAB
(n = 261) and GENESIS (n = 549) participants were
followed until an end point was reached, or until February
2007. The subsets were composed of participants who
attended outpatient clinics at least once during the follow-
up period. In the present investigation, we analyzed
follow-up data from 259 GENEDIAB participants and 525
GENESIS probands for whom DNA samples were avail-
able. Mean duration of follow-up was 9 ± 3 and 5 ± 2 years,
respectively.
Participants: the DIABHYCAR cohort of type 2 diabetic
patients
DIABHYCAR (non-insulin-dependent DIABetes, HYper-
tension, microalbuminuria or proteinuria, CArdiovascu-
lar events, and Ramipril) was a multinational clinical
trial conducted in patients with type 2 diabetes selected
on the basis of persistent microalbuminuria (urinary al-
bumin excretion, UAE = 20-200 mg/l) or macroalbumi-
nuria (UAE > 200 mg/l) without renal failure (plasma
creatinine <150 μmol/l) at baseline [14]. The trial tested
whether a low dose of ramipril, an angiotensin convert-
ing enzyme (ACE) inhibitor, able to reduce UAE would
also reduce cardiovascular and/or renal events such as
myocardial infarction, stroke, acute heart failure, end-
stage renal disease (ESRD), and cardiovascular death.
The median duration of follow-up was 4.7 years. Results
were negative regarding the drug effect and were pub-
lished previously [14]. In the present work, we studied
3137 French participants of DIABHYCAR. Study proto-
cols of the three cohorts were approved by the ethics
committee of the University Hospital of Angers, France.
All participants gave written informed consent.
Outcomes
Myocardial infarction was diagnosed as the occurrence
of at least 2 out of 3 of the following criteria: constrictive
chest pain lasting 20 minutes or longer, increased serum
creatinine phosphokinase and/or troponine levels, or
typical electrocardiographic changes. All-cause mortality
was defined as death from any cause occurring during
follow-up. Cardiovascular death was defined as sudden
death, death following myocardial infarction, congestive
heart failure and arrhythmias.
Clinical and laboratory procedures
Estimation of the glomerular filtration rate (eGFR) was
computed with the Modification of Diet in Renal Disease
(MDRD) formula. Plasma concentrations of EC-SOD,
AOPP and isoprostane were measured in 440 GENE-
DIAB participants for whom fasting plasma-EDTA sam-
ples were available. Samples were collected at baseline
and kept frozen at −80°C. EC-SOD was measured by
ELISA as described previously [15]. Isoprostane was
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tane F2t ELISA Kit EA84, Oxford Biomedical Research).
AOPP were measured by spectrophotometry using a mi-
croplate reader (MR 5000, Dynatech, Paris, France) [16].
Results were expressed as ng/ml (EC-SOD and isopros-
tane) and μmol/L of chloramine-T equivalents (AOPP).
Five single nucleotide polymorphism (SNP) in the
SOD3 gene region (chromosome 4q21) were chosen in
HapMap (public release #23) on the basis of giving in-
formation on ~90% of the allelic variation of SNPs with
minor allele frequency ≥5% at r2 > 0.8 in haplotype
blocks containing SOD3: rs2284659 (promoter, ~2.3 kb
5’ from exon 1 start), rs2695234, rs17552548, rs758946
and rs2270224 (respectively ~1.8, ~2.3, ~4.8 and ~5.9 kb
3’ from the end of exon 2/UTR). The rare missense
functional variant rs1799895 (Arg213Gly, exon 2) was
also genotyped [17]. Genotypes were determined by
competitive allele-specific PCR genotyping system assays
(KASP, LGC Genomics, Hoddeston, UK). Genotyping
success rate was >92%. Genotyping was repeated in 5%
of subjects with 100% concordance. Genotypes were in
Hardy-Weinberg equilibrium (Pearson’s chi-squared test
with 1 degree of freedom p > 0.05) except for rs2695234
and rs2270224 in the DIABHYCAR cohort.
Statistical analysis
Results are expressed as mean ± SEM except where
stated otherwise. Differences between groups were assessed
by analysis of variance (ANOVA), analysis of covariance
(ANCOVA), and contingency table chi-square test. Genetic
associations were assessed by regression models. Cox pro-
portional hazards survival regression analyses were used to
examine the effect of explanatory variables on time-related
survival (or myocardial infarction-free) rates in prospective
analyses. Logistic regression analyses were used for cross-
sectional analyses. Hazard ratios (HR) or odds ratios (OR),
respectively, with their 95% confidence intervals (CI) were
computed for the minor alleles. The choice of a genetic
model (dominant, codominant or recessive) for each of the
analyses was based on the prevalence and/or incidence of
the traits (myocardial infarction, all-cause mortality) by
genotype. HR or OR were not computed for SNP with
minor allele frequency (MAF) lower than 2% in the groups
being compared, nor for genotypes not in Hardy-Weinberg
equilibrium. Data were log-transformed for the analyses
when the normality of the distribution was rejected by the
Shapiro-Wilk W test. To increase statistical power, genetic
analyses in type 1 diabetic participants were performed in
GENEDIAB and GENESIS pooled studies with appropriate
covariate adjustments to take into account cohort differ-
ences. Correction for multiple comparisons due to multiple
SNP testing took into account the effective number of in-
dependent tests (Meff) based on the degree of linkage
disequilibrium between SNPs [18]. Thus, p ≤ 0.01 wasconsidered significant, unless stated otherwise. The power
to detect allelic associations with the prevalence and the in-
cidence of myocardial infarction, and with all-cause mor-
tality in the GENEDIAB/GENESIS pooled study, was 90,
82 and 81%, respectively, for hazard ratio ≥1.5 and alpha =
0.01. It was 99% for each outcome in DIABHYCAR cohort.
Statistics were performed with the JMP software (SAS
Institute Inc., Cary, NC).
Results
GENEDIAB and GENESIS cohorts: previous myocardial
infarction at baseline by SOD3 genotype
The prevalence of previous myocardial infarction at
baseline in the pooled cohorts of patients with type 1
diabetes was 5.8% (n = 62). Genotype frequencies by his-
tory of previous myocardial infarction at baseline are
shown in the Additional file 1: Table S2. The prevalence
of myocardial infarction by rs2284659 genotype was 7.0%
(GG), 5.4% (GT) and 2.2% (TT) suggesting a protective ef-
fect of the minor T-allele in a codominant model. A logis-
tic regression analysis confirmed the inverse association of
the T-allele with the prevalence of previous myocardial in-
farction (OR 0.48, 95% CI 0.29–0.78, p = 0.004, in a co-
dominant model adjusted for sex, age, duration of diabetes,
use of antihypertensive and lipid lowering medications,
and for cohort membership).
GENEDIAB and GENESIS cohorts: clinical outcomes during
follow-up
Characteristics of participants at baseline by the inci-
dence of clinical outcomes during follow-up are shown
in Table 1. Forty nine new cases of myocardial infarction
occurred during follow-up. Its cumulative incidence was
6.3% (incidence rate 1.0 per 100 person-years). Individ-
uals who had a myocardial infarction, compared to those
who did not, were older, had a longer duration of dia-
betes, higher systolic blood pressure, lower eGFR, and
were more likely to be of the male sex and to be taking
antihypertensive and lipids lowering drugs. Previous
myocardial infarction was more frequent at baseline in
participants who developed new cases of myocardial in-
farction during the follow-up, as compared to those who
did not. Death occurred in 72 participants during the
follow-up. The cumulative incidence of total mortality
was 9.2% (incidence rate 1.4 per 100 person-years).
Causes of death included cardiovascular complications
(38.9%), infectious diseases (15.3%), cancer (9.7%), acute
metabolic complications (8.3%), kidney complications
(2.8%) and other or undetermined etiologies (25.0%).
Participants who died during follow-up, as compared to
subjects who survived, were older, more frequently of
the male sex, had a longer duration of diabetes, higher
HbA1c, systolic and diastolic blood pressure, and UAE
levels. They had lower eGFR and were more likely to
Table 1 GENEDIAB/GENESIS pooled study: Characteristics of participants at baseline by the incidence of myocardial
infarction and all-cause mortality during follow-up
Myocardial Infarction during follow-up All-cause mortality
No Yes p No Yes p
N 735 49 712 72
Male sex (%) 53.8 69.4 0.03 53.7 70.8 0.005
Age (years) 42.6 ± 11.0 52.3 ± 12.5 <0.0001 42.7 ± 11.1 49.5 ± 12.6 <0.0001
Duration of diabetes (years) 27.1 ± 9.0 33.3 ± 11.6 0.0004 27.2 ± 9.1 31.3 ± 10.6 0.004
Body mass index (kg/m2) 24.2 ± 3.5 24.9 ± 3.7 0.24 24.4 ± 3.5 23.6 ± 3.8 0.07
Systolic blood pressure (mmHg) 134 ± 19 144 ± 21 0.0007 134 ± 19 142 ± 18 0.0005
Diastolic blood pressure (mmHg) 77 ± 11 80 ± 11 0.07 76 ± 11 80 ± 10 0.004
HbA1c (%) and (mmol/mol) 8.5 ± 1.5 (70 ± 16) 8.9 ± 1.5 (74 ± 16) 0.08 8.5 ± 1.4 (69 ± 15) 9.4 ± 2.3 (79 ± 25) <0.0001
Urinary albumin excretion (mg/l) 21 (177) 43 (836) 0.22 19 (157) 188 (900) <0.0001
eGFR (ml/min) 86 ± 47 70 ± 31 0.02 86 ± 46 69 ± 56 <0.0001
Total cholesterol* (mmol/l) 5.67 ± 1.51 5.91 ± 1.07 0.28 5.65 ± 1.42 5.76 ± 1.67 0.97
Lipids lowering therapy (%) 7.9 16.3 0.04 8.3 11.1 0.41
Tobacco smoking (%) 42.0 47.9 0.42 41.2 59.2 0.004
Arterial hypertension (%) 60.8 83.7 0.001 60.5 84.7 <0.0001
Previous myocardial infarction (%) 3.8 22.9 <0.0001 3.9 21.1 <0.0001
Results expressed as mean ± SD, except urinary albumin excretion (UAE) expressed as median and interquartile range. Statistics of quantitative parameters are
ANOVA performed with log-transformed data, or Wilcoxon test (UAE). eGFR: estimated glomerular filtration rate. *Data available only in the GENEDIAB cohort
(n = 247). p < 0.05 is significant.
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sion and myocardial infarction.GENEDIAB and GENESIS cohorts: clinical outcomes during
follow-up by SOD3 genotypes
Genotype frequencies by the incidence of clinical out-
comes during follow-up are shown in Table 2. The inci-
dence of myocardial infarction by rs2284659 genotype
was 7.6% (GG), 5.4% (GT) and 5.6% (TT), suggesting a
protective effect of the minor T-allele in a dominant
model. Cox proportional hazards survival regression
analysis confirmed the inverse associations of rs2284659
T-allele with the incidence of myocardial infarction (HR
0.58, 95% CI 0.40–0.83, p = 0.003, in a dominant model,
adjusted for sex, age, duration of diabetes, blood pres-
sure, HbA1c, UAE, eGFR, use of antihypertensive and
lipid lowering medications, tobacco smoking and cohort
membership). The incidence of all-cause mortality by
rs2284659 genotype was 8.9% (GG), 10.3% (GT) and
4.3% (TT), suggesting a protective effect of the minor T-
allele in a recessive model. The association was con-
firmed by a Cox proportional hazards survival regression
analysis (HR 0.44, 95% CI 0.21–0.73, p = 0.0006, for the
T-allele in a recessive model adjusted for the same co-
variates as above). The T-allele protective effect
remained significant when we considered only the cases
of cardiovascular death (HR 0.33, 95% CI 0.08–0.74, p =0.004). No other significant allelic association was ob-
served with any of the outcomes.GENEDIAB cohort: baseline correlations of EC-SOD and
markers of oxidative stress
Plasma EC-SOD concentration at baseline was higher in
women than in men (226 ± 18 vs 176 ± 11 ng/ml,
p = 0.0004). It was positively correlated with systolic
(R2 = 0.04, p < 0.0001) and diastolic blood pressure
(R2 = 0.03, p < 0.0001), UAE (R2 = 0.03, p = 0.001), total
cholesterol (R2 = 0.03, p = 0.0001), and inversely corre-
lated with the body mass index (BMI; R2 = 0.02,
p = 0.004) and eGFR (R2 = 0.12, p = 0.001). A stepwise
regression analysis was performed to evaluate the
independence of these correlations (Additional file 1:
Table S3). Plasma EC-SOD concentration was entered in
the model as the dependent variable. Age, duration of
diabetes, HbA1c and the above mentioned variables
were entered as independent covariates. Only eGFR, sex,
systolic blood pressure, and BMI remained significantly
correlated with EC-SOD and explained ~20% of the
variance of the trait.
Plasma AOPP concentration at baseline was higher in
women than in men (70 ± 3 vs 63 ± 2 μmol/l, p = 0.02), and
was lower in subjects treated by ACE inhibitors (46 ± 3 vs
80 ± 2 μmol/l, p < 0.0001) or antihypertensive drugs
(57 ± 36 vs 79 ± 29 μmol/l, p < 0.0001) than in subjects
Table 2 GENEDIAB/GENESIS pooled study: genotype frequency of SOD3 variants by the incidence of myocardial
infarction and all-cause mortality during follow-up
Myocardial Infarction during follow-up All-cause mortality
No Yes HR (95% C.I.) p No Yes HR (95% C.I.) p
rs2284659
GG 0.413 (268) 0.500 (22) 0.45 (0.25 – 0.77) 0.003 0.412 (265) 0.413 (26) 0.44 (0.21 – 0.73) 0.0006*
GT 0.456 (297) 0.386 (17) 0.448 (289) 0.524 (33)
TT 0.131 (85) 0.114 (5) 0.140 (90) 0.063 (4)
MAF 0.359 0.307 0.364 0.325
rs1799895
CC 0.983 (638) 1.000 (42) - ** 0.983 (628) 1.000 (65) - **
CG 0.017 (11) 0 (0) 0.017 (11) 0.000 (0)
GG 0 0 (0) 0 0 (0)
MAF 0.008 0 0.009 0
rs2695234
GG 0.861 (566) 0.930 (40) 0.54 (0.09 – 1.70) 0.34 0.858 (558) 0.922 (59) 0.65 (0.32 – 1.08) 0.10
GA 0.130 (85) 0.047 (2) 0.133 (86) 0.062 (4)
AA 0.009 (6) 0.023 (1) 0.009 (6) 0.016 (1)
MAF 0.074 0.047 0.076 0.047
rs17552548
AA 0.894 (575) 0975 (39) - ** 0.904 (574) 0.857 (54) 1.47 (0.99 – 2.06) 0.06
GA 0.104 (67) 0.025 (1) 0.094 (60) 0.143 (9)
GG 0.002 (1) 0 (0) 0.002 (1) 0 (0)
MAF 0.054 0.013 0.049 0.071
rs758946
TT 0.857 (553) 0.930 (40) 0.49 (0.08 – 1.52) 0.25 0.853 (544) 0.936 (59) 0.68 (0.33 – 1.13) 0.15
TC 0.135 (87 0.047 (2) 0.138 (88) 0.064 (4)
CC 0.008 (5) 0.023 (1) 0.009 (6) 0 (0)
MAF 0.075 0.047 0.078 0.032
rs2270224
GG 0.270 (169) 0.136 (6) 1.12 (0.65 – 1.91) 0.68 0.257 (158) 0.303 (20) 0.75 (0.50 – 1.04) 0.09*
GA 0.483 (304) 0.682 (30) 0.495 (306) 0.530 (35)
AA 0.247 (155) 0.182 (8) 0.248 (153) 0.167 (11)
MAF 0.489 0.523 0.496 0.432
Genotype data expressed as frequency and (number of cases). SNPs are sorted in 5’ to 3’ order. Hazards ratio for the minor allele in a dominant or recessive* model,
determined in Cox proportional hazards survival regressive model, adjusted for sex, age, duration of diabetes, blood pressure, HbA1c, UAE, eGFR, use of antihypertensive and
lipid lowering medications, tobacco smoking and cohort membership. p ≤ 0.01 is significant. MAF: minor allele frequency. **Statistics not computed due to low MAF (<0.02).
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lated with total cholesterol levels (R2 = 0.05, p < 0.0001).
Only the use of ACE inhibitors, and total cholesterol levels
remained significantly correlated with AOPP concentra-
tion in a stepwise regression analysis and explained 38%
and 6%, respectively, of its variance (data not shown).
Plasma isoprostane concentration was higher in subjects
treated by lipid lowering drugs than in those who
were not (2.13 ± 0.20 vs 1.61 ± 0.05 ng/ml, p = 0.005). It
was positively correlated with diastolic blood pressure
(R2 = 0.02, p = 0.004).GENEDIAB cohort: EC-SOD and markers of oxidative stress
at baseline by clinical outcomes during follow-up
Circulating levels of EC-SOD, AOPP and isoprostane
at baseline by clinical outcomes during follow-up are
shown in Table 3. Plasma EC-SOD concentration was
not significantly associated with clinical outcomes dur-
ing follow-up. Plasma AOPP concentration was higher
in patients who died during the follow-up as compared
to those who survived. Plasma isoprostane concentra-
tion was significantly higher in subjects who presented
a clinical outcome (myocardial infarction or death
Table 3 GENEDIAB cohort: Plasma EC-SOD, AOPP and Isoprostane concentrations by clinical outcomes during follow-up
N EC-SOD (ng/ml) N AOPP (μmol/l) N Isoprostane (ng/ml)
Myocardial infarction
Yes 25 194 ± 44 26 60 ± 6 26 2.37 ± 0.24
No 208 196 ± 15 214 66 ± 2 226 1.52 ± 0.08
p 0.51 0.49 0.0003
All-cause mortality
Yes 47 195 ± 30 40 73 ± 6 42 2.22 ± 0.20
No 194 192 ± 14 209 56 ± 4 221 1.71 ± 0.12
p 0.57 0.004 0.002
Results expressed as mean ± SEM. Statistics are ANCOVA adjusted for sex, age, BMI, systolic blood pressure and eGFR (EC-SOD), for sex, age, total cholesterol
concentration, and use of ACE inhibitors (AOPP), and for sex, age, diastolic blood pressure, and use of lipid lowering drugs (isoprostane). p < 0.05 is significant.
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who did not.GENEDIAB cohort: EC-SOD and markers of oxidative stress
at baseline by SOD3 genotypes
Genotype-related effects on EC-SOD, AOPP and iso-
prostane are shown in Table 4. Carriers of the protective
T-allele of rs2284659 had significantly higher plasma
EC-SOD concentration than homozygous GG carriers.
Moreover, carriers of the TT genotype had significantly
lower plasma AOPP concentration than G-allele carriers.
Heterozygous carriers of the rare G-allele of the missense
(Arg213Gly) functional variant rs1799895 had a ~6-fold
increase in plasma EC-SOD concentration. Higher plasma
AOPP concentration was also observed for GG carriers of
rs2270224 and G-allele carriers of rs17552548 (p < 0.0001;
data not shown). We observed no genotype-related associ-
ation with plasma isoprostane concentration.Table 4 GENEDIAB cohort: Plasma EC-SOD, AOPP and
Isoprostane concentrations at baseline by SOD3 genotypes
EC-SOD (ng/ml) AOPP (μmol/l) Isoprostane (ng/ml)
rs2284659
GG (n) 165 ± 17 (165) 66 ± 3 (156) 1.98 ± 0.11 (162)
GT (n) 230 ± 16 (172) 64 ± 3 (171) 1.92 ± 0.11 (181)
TT (n) 222 ± 25 (74) 55 ± 4 (73) 1.98 ± 0.16 (73)
p 0.007 0.02 0.90
rs1799895
CC (n) 169 ± 6 (400) 64 ± 2 (390) 1.93 ± 0.10 (407)
CG (n) 1156 ± 32 (12) 52 ± 10 (12) 1.78 ± 0.34 (12)
p <0.0001 0.34 0.41
Results expressed as mean ± SEM. Statistics are ANCOVA adjusted for sex, age,
BMI, systolic blood pressure and eGFR (EC-SOD), for sex, age, total cholesterol
concentration, and use of ACE inhibitors (AOPP), and for sex, age, diastolic
blood pressure, and use of lipid lowering drugs (isoprostane). p ≤ 0.01
is significant.DIABHYCAR study: clinical outcomes during follow-up by
SOD3 genotype
Myocardial infarction was diagnosed in 95 participants
and death occurred in 456 participants during the
follow-up of the DIABHYCAR type 2 diabetes study.
The cumulative incidence of myocardial infarction and
total mortality was 3.0% and 14.5%, respectively, and
their incidence rate was 0.7 and 3.3 per 100 person-
years. Causes of death included cardiovascular complica-
tions and sudden death (40.0%), infectious diseases
(2.4%), cancer (26.5%), acute metabolic complications
(0.2%), end stage renal disease (ESRD, 0.9%) and other
or undetermined etiologies (30.0%). Characteristics of
participants at baseline by the incidence of myocardial
infarction and all-cause mortality during the follow-up
are shown in Table 5. Patients who died during follow-
up, as compared to those who survived, were older,
more frequently of the male sex, had a longer duration
of diabetes, higher systolic blood pressure and UAE
levels. They had lower BMI and eGFR levels, and were
more likely to be taking antiplatelet drugs, and to have a
previous history of hypertension and myocardial infarc-
tion. Genotype frequencies by the incidence of clinical
outcomes during follow-up are shown in Additional file
1: Table S4. The incidence of outcomes by rs2284659
genotype was 3.6% (GG), 2.6% (GT) and 2.3% (TT) for
myocardial infarction, and 16.3% (GG), 13.4% (GT) and
14.1% (TT) for all-cause mortality, suggesting a protect-
ive effect of the minor T-allele in a dominant model.
Cox proportional hazards survival regression analyses
confirmed the inverse associations of rs2284659 T-allele
with the incidence of myocardial infarction (HR 0.75,
95% CI 0.59–0.94, p = 0.01) and all-cause mortality (HR
0.87, 95% CI 0.79–0.97, p = 0.008) in a dominant model,
adjusted for sex, age, duration of diabetes, BMI, blood
pressure, UAE, eGFR, hypertension and antiplatelet
drugs and study treatment. A nominal inverse associ-
ation was also observed when we considered only car-
diovascular causes of death (HR 0.83, 95% CI 0.69–0.99,
Table 5 DIABHYCAR cohort: Characteristics of participants at baseline by the incidence of myocardial infarction and
all-cause mortality during follow-up
Myocardial infarction during follow-up All-cause mortality
No Yes p No Yes p
N 3042 95 2554 438
Male sex (%) 73.0 75.8 0.54 72.2 77.2 0.03
Age (years) 65.6 ± 8.3 65.9 ± 8.8 0.79 64.8 ± 8.1 70.5 ± 8.5 <0.0001
Duration of diabetes (years) 10.4 ± 7.7 11.3 ± 8.6 0.49 10.1 ± 7.6 12.3 ± 8.2 <0.0001
Body mass index (kg/m2) 29.4 ± 4.6 29.1 ± 4.2 0.60 29.5 ± 4.6 28.8 ± 4.9 0.0008
Systolic blood pressure (mmHg) 144 ± 13 146 ± 16 0.14 144 ± 13 146 ± 13 0.007
Diastolic blood pressure (mmHg) 82 ± 8 81 ± 8 0.29 82 ± 8 82 ± 8 0.99
HbA1c (%) and (mmol/mol) 7.9 ± 1.8 (62 ± 19) 8.2 ± 1.8 (66 ± 20) 0.06 7.8 ± 1.7 (62 ± 19) 8.0 ± 2.0 (64 ± 22) 0.35
Urinary albumin excretion (mg/l) 76 (144) 78 (162) 0.92 72 (130) 109 (278) <0.0001
eGFR (ml/min) 78 ± 22 75 ± 20 0.14 78 ± 22 72 ± 21 <0.0001
Total cholesterol (mmol/l) 5.79 ± 1.07 6.00 ± 1.25 0.18 5.78 ± 1.05 5.84 ± 1.15 0.37
HDL- cholesterol (mmol/l) 1.32 ± 0.36 1.25 ± 0.26 0.15 1.32 ± 0.35 1.29 ± 0.34 0.17
LDL- cholesterol (mmol/l) 3.52 ± 0.88 3.72 ± 1.02 0.10 3.53 ± 0.87 3.51 ± 0.92 0.61
Triglycerides (mmol/l) 1.83 (1.36) 1.81 (1.77) 0.53 1.84 (1.32) 1.84 (1.49) 0.69
Lipids lowering therapy (%) 35.5 33.7 0.71 36.0 32.2 0.12
Antiplatelet drugs (%) 18.8 16.8 0.63 17.0 28.5 <0.0001
Tobacco smoking (%) 14.4 13.7 0.84 14.2 14.6 0.83
Arterial hypertension (%) 56.1 60.0 0.44 54.9 64.4 0.0002
Previous myocardial infarction (%) 5.3 10.5 0.03 4.9 8.5 0.003
Results expressed as mean ± SD, except urinary albumin excretion (UAE) and triglycerides expressed as median and interquartile range. Statistics of quantitative
parameters are ANOVA performed with log-transformed data, or Wilcoxon test (UAE, triglycerides). eGFR: estimated glomerular filtration rate. p < 0.05 is significant.
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Discussion
In the present investigation, we observed associations of
a variant in the promoter region of the SOD3 gene with
cardiovascular morbidity and mortality in prospective
cohorts of type 1 and type 2 diabetic patients. The minor
T-allele of rs2284659 was inversely associated with the
prevalence of myocardial infarction at baseline and with
the incidence during follow-up of myocardial infarction,
cardiovascular death and all-cause mortality in subjects
with type 1 diabetes from GENESIS and GENEDIAB
studies. The same allele was also inversely associated
with the incidence of myocardial infarction and all-cause
mortality during follow-up in the DIABHYCAR cohort
of type 2 diabetic subjects. The protective T-allele of
rs2284659 was associated with higher plasma EC-SOD
and lower plasma AOPP concentrations in GENEDIAB.
AOPP concentration reflects the oxidation of plasma
proteins, especially albumin, and is a reliable marker of
oxidant-mediated protein damage [16]. Isoprostanes are
a biologically active product of arachidonic acid metab-
olism formed as the result of oxygenation of polyunsat-
urated fatty acids. Circulating isoprostane concentrationreflects lipid peroxidation associated with oxidative
stress [11]. We observed higher plasma AOPP and iso-
prostane concentrations at baseline in type 1 diabetic
subjects who died during the follow-up than in subjects
who were alive at the end of the study. Isoprostane con-
centration at baseline was also higher in incident case of
myocardial infarction. Previous studies have shown
plasma AOPP and isoprostane to be an independent risk
factors for coronary artery disease [10,11,19,20].
SOD3 gene and risk of cardiovascular morbidity
and mortality
Data from the literature on the association of the genes
encoding the SOD enzymes with cardiovascular compli-
cations are scare. We have previously observed in the
DIABHYCAR cohort associations of SOD1 variants with
cardiovascular mortality [21]. Mollsten and coworkers
observed an association of a missense variant of SOD2
with increased cardiovascular risk in a Danish cohort of
type 1 diabetic patients [22]. Regarding SOD3, investiga-
tions dealt mostly with the rare functional variant
rs1799895 (Arg213Gly) in the heparin-binding domain
of EC-SOD. The Gly allele is associated with decreased
EC-SOD affinity for heparin, decreased tissue binding,
and a 6-to-10-fold increase in circulating EC-SOD
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levels of the enzyme, the 213Gly isoform was shown to
present only minimal anti-oxidant effects in the vascular
wall [24], the loss of function being attributed to de-
creased tissue binding. Associations of the Gly allele
with cardiovascular risk factors, morbidity or mortality
were reported in a few studies [25,26].
Genetic analysis of rs1799895 in our study was incon-
clusive due to the very low frequency of the Gly allele in
our cohorts. It is therefore unlikely that the associations
we have observed with the promoter rs2284659 could be
explained by a rs1799895 Gly allele effect. Moreover,
linkage disequilibrium between the two variants was not
strong (D’ = 0.687 and r2 = 0.009). The genetic mechan-
ism behind the allelic associations that we have observed
remains unclear, as rs2284659 does not seem to modify
known transcription factor binding sites. However, it is
noteworthy that rs2284659 is in complete linkage dis-
equilibrium with two other SNPs in the promoter of
SOD3 (rs2159757 and rs13435617) that might affect
transcription. The region surrounding and including
rs2159757 matches the binding site for the PBX (pre-B-
cell leukemia) family of transcription factors, and that
surrounding and including rs13435617 matches the
binding sites for HLF (hepatic leukemia factor) and
E4BP4 (adenovirus E4 promoter-binding protein) tran-
scription factors (http://consite.genereg.net). Interest-
ingly, PBX transcription factors play a significant role in
the morphogenesis, patterning and formation of the ven-
tricular outflow tract (OFT). Mice lacking PBX1 gene
have a range of OFT malformations, including failure of
cardiac septation [27]. A missense variant of PBX3 (p.
A136V) predicted to be deleterious for transcriptional
function was four times more frequent in patients with
congenital heart defects as compared to controls [28].
E4BP4 is implicated in the regulation of mammalian circa-
dian oscillatory mechanism, anti-inflammatory response
and cell survival. E4BP4 is expressed in the human heart
and was shown to inhibit apoptotic proteins and to be
overexpressed in cardiomyocytes following myocardial in-
farction [29]. The implication of these transcription factors
on SOD3 expression needs to be evaluated.
Oxidative stress and vascular complications of diabetes
Oxidative stress is involved in the pathogenesis of athero-
sclerosis [30]. Increased production of reactive oxygen spe-
cies (ROS) impairs endothelial function and endothelium-
dependent vasodilation in humans, notably by inactivation
of NO [31,32]. Oxidative stress also induces cell prolifera-
tion, hypertrophy, cardiac remodeling, apoptosis and in-
flammation in endothelial and smooth cells of the vascular
wall and in myocardial cells [31,33,34]. Moreover, oxidative
stress is associated with the metabolic syndrome and with
many risk factors for atherosclerosis such as hypertension,dyslipidemia, obesity and diabetes [35]. Biomarkers of oxi-
dative stress predict the risk of mortality in patients with
heart disease [36]. Oxidative stress was shown to play a
role in the premature vascular morbidity and mortality in
people with diabetes [37]. Studies in animal models corrob-
orate the implication of oxidative stress in cardiovascular
morbidity and mortality related to diabetes [38,39].
Antioxidant enzymes such as the SODs scavenge ROS
and inhibit NO degradation in the vascular wall [33].
The vascular wall contains large amounts of EC-SOD,
which is produced and secreted to the extracellular
space by smooth muscle cells [7,40]. The expression of
SOD3 was shown to be significantly reduced, and
endothelium-bound EC-SOD activity to be correlated to
flow-dependent endothelium-mediated dilation in sub-
jects with coronary artery disease, suggesting that re-
duced EC-SOD activity might contribute to endothelial
dysfunction in these patients [8]. Overexpression of
SOD3 in human vascular endothelial cells in vitro was
shown to decrease endothelial-cell-derived superoxide
production and LDL oxidation [9]. The implication of
EC-SOD in cardiovascular protection is supported by
studies in animal models. The overexpression of SOD3
in transgenic mice was associated with protection of
myocardial function after global ischemia/reperfusion
[41]. Increased EC-SOD levels by adenovirus-mediated
transfection of human SOD3 cDNA was associated with
protection against myocardial stunning and with de-
creased reperfusion infarct size in a rabbit model of is-
chemia/reperfusion injury [42]. Atherosclerosis was not
increased in SOD3 knockout mice given an atherogenic
diet [43]. However, in an experimental model of focal cere-
bral ischemia, total infarct volume was 81% greater and
hemiparesis more severe in SOD3 knockout mice as com-
pared to wild-type animals [44], while mice overexpressing
SOD3 had increased resistance to ischemia [45].
Strengths and limitations
The main strengths of our study are the assessment of
clinical phenotypes (myocardial infarction, cardiovascu-
lar and all-cause mortality) in three prospective cohorts
of type 1 and type 2 diabetes and the genotyping of
tagSNPs covering the haplotype block containing SOD3.
We also investigated associations of the clinical pheno-
types and SOD3 genotypes with three markers of redox
status. Overproduction of ROS and oxidative stress in-
duced by chronic hyperglycemia are features of type 1
and type 2 diabetes [5]. Nevertheless, despite the obser-
vation in our study of similar genetic associations in
both types of diabetes, we acknowledge that proper rep-
lication studies are needed in type 1 and type 2 diabetes
cohorts. Our study has limitations, notably in issues re-
lated to the measurement of the redox biomarkers.
AOPP and isoprostane were assayed in plasma-EDTA
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and only in a subset of participants. These issues might
have affected, at least in part, comparisons of plasma
AOPP and isoprostane concentrations between groups.
Moreover, measurements of redox biomarkers were per-
formed only in GENEDIAB participants for whom plasma
samples were available, and thus were not replicated in
the present investigation. Another limitation of the study
is the relatively small sample size of our type 1 diabetes
cohorts and the small number of new cases of myocardial
infarction during follow-up. The statistical power was ad-
equate to detect SNP effects with HR ≥1.5, but might have
been insufficient to detect effects of smaller magnitude.
Conclusions
We have observed associations of rs2284659 in the pro-
moter of the SOD3 gene with myocardial infarction and
with cardiovascular and all-cause mortality in subjects
with type 1 or type 2 diabetes. The protective allele was
associated with increased EC-SOD and decreased AOPP
plasma concentrations, and thus with a more favorable
plasma redox status. Our results suggest that EC-SOD
plays a role in the mechanisms of vascular protection
against oxidative stress in diabetic patients. Further studies
are required to identify the functional variants and the
molecular mechanisms beyond these allelic associations.Additional file
Additional file 1: Supplemental Tables.
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